Novo Nordisk to Reduce Prices for Wegovy and Ozempic in U.S. Next Year

Novo Nordisk has announced plans to lower the U.S. list prices for its popular obesity treatments, Wegovy and Ozempic, starting next year. Bloomberg posted on X, highlighting the company's strategy to regain a larger portion of the obesity market. The decision comes as Novo Nordisk faces challenges in maintaining its market share amid increasing competition. The price reduction is part of a broader effort to make these medications more accessible to patients and strengthen the company's position in the industry. Novo Nordisk's move reflects the growing demand for effective obesity treatments and the competitive landscape in the pharmaceutical sector.